PureTech Health announced a proposed capital return of $100M to its shareholders by way of a tender offer. The capital return of $100M represents approximately 14% of PureTech’s market capitalization based on yesterday’s closing price. This follows the company’s announcement that it will receive approximately $293M gross proceeds from its remaining stake in Karuna. The tender offer will be launched after the publication of the company’s FY24 results in April, subject to market conditions, and will require shareholder approval. A circular setting out the full terms of the tender offer and a timetable will be published upon launch. If the full $100M is not returned, then the company intends to return any remainder following the completion of the tender offer, by way of a special dividend.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRTC:
- PureTech Health Entity Acquired for $14 Billion
- FDA grants PureTech Health an ODD to LYT-200 for AML treatment
- PureTech Health treatment of Acute Myeloid Leukemia granted FDA orphan status
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue